Cardiac Myxoma

Comprehensive Clinical Guide: Cardiac Myxoma

Cardiac myxoma is the most common primary cardiac tumor in adults. While histologically benign, its clinical behavior can be aggressive, often mimicking systemic inflammatory diseases, infective endocarditis, or metastatic malignancy. Because of its propensity for intracardiac obstruction, embolic events, and systemic constitutional symptoms, cardiac myxoma is considered a "benign tumor with malignant potential" that demands surgical intervention.

1. Clinical Definition and Overview

A cardiac myxoma is a pedunculated, gelatinous, and friable benign neoplasm primarily arising from the endocardial surface. Approximately 75% of these tumors originate in the left atrium, specifically attached to the interatrial septum at the border of the fossa ovalis.

Epidemiological Profile

• Incidence: Occurs in approximately 0.5 to 1 per million population annually.
• Age of Onset: Most commonly diagnosed in the third to sixth decades of life.
• Gender Predisposition: Sporadic myxomas are significantly more common in females (female-to-male ratio of approximately 3:1).
• Genetic Association: Familial cases, often associated with Carney Complex (CNC), typically present in younger patients and exhibit a higher rate of recurrence.

2. Pathophysiology and Mechanisms

The pathogenesis of cardiac myxoma is rooted in the neoplastic transformation of multipotent mesenchymal cells. These cells possess the capability to differentiate into various cell types, explaining the heterogeneous structural composition of the tumor.

Cellular Composition

• Myxoma Cells: Small, stellate, or spindle-shaped cells embedded in a myxoid stroma.
• Matrix: Abundant glycosaminoglycans (hyaluronic acid and chondroitin sulfate), which contribute to the tumor's gelatinous consistency.
• Surface Characteristics: The surface is often covered by a layer of endothelium, but it is frequently friable, which leads to the high risk of embolization.

Molecular Drivers

In familial cases (Carney Complex), the primary genetic driver is a germline mutation in the PRKAR1A gene, which encodes the regulatory subunit of Protein Kinase A. This mutation leads to constitutive activation of the PKA pathway, driving cellular proliferation.

3. Clinical Presentation: The "Great Masquerader"

The clinical presentation of cardiac myxoma is classically categorized into three distinct syndromes:

A. Obstructive Symptoms

These result from the tumor’s physical movement into the mitral valve orifice during diastole, simulating mitral stenosis.
* Dyspnea on exertion.
* Paroxysmal nocturnal dyspnea.
* Syncope or dizziness.
* Positional changes in symptoms (e.g., relief when lying supine vs. standing).

B. Embolic Events

Because the tumor is friable, fragments can break off and travel through the systemic circulation.
* Cerebral: Stroke or transient ischemic attack (TIA).
* Peripheral: Digital ischemia, splenic or renal infarction.
* Pulmonary: Rare (usually associated with right-sided myxomas).

C. Constitutional/Systemic Symptoms

These are mediated by the tumor's production of Interleukin-6 (IL-6), which triggers a systemic inflammatory response.
* Fever of unknown origin (FUO).
* Weight loss and cachexia.
* Arthralgia and myalgia.
* Elevated Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP).
* Anemia of chronic disease.

4. Clinical Staging and Differential Diagnosis

Unlike malignant tumors, myxomas do not have a formal TNM staging system. Instead, they are classified by location and syndromic association.

Differential Diagnosis Table

5. Diagnostic Workup

The diagnosis of cardiac myxoma requires a high index of suspicion.

Standard Diagnostic Modalities

1. Transthoracic Echocardiography (TTE): First-line investigation. Usually identifies the mass, its mobility, and its impact on valve hemodynamics.
2. Transesophageal Echocardiography (TEE): The gold standard for visualizing the attachment site (interatrial septum), the stalk, and the tumor's exact morphology.
3. Cardiac MRI (CMR): Highly effective for tissue characterization. Myxomas typically show heterogeneous enhancement on delayed gadolinium enhancement.
4. Cardiac CT: Useful for preoperative planning to assess coronary artery anatomy and the extent of attachment.

6. Risks, Side Effects, and Surgical Management

The standard of care for cardiac myxoma is urgent surgical excision.

Surgical Risks

• Embolization during manipulation: The most critical risk during sternotomy. The heart must be handled with extreme care to avoid dislodging fragments.
• Arrhythmias: Post-operative atrial fibrillation is common.
• Recurrence: Occurs in 1–5% of sporadic cases but up to 20% in familial cases.

Contraindications to Surgery

There are virtually no absolute contraindications to the removal of a cardiac myxoma, as the risk of sudden death from valvular obstruction or major embolic stroke outweighs the surgical risk.

7. Long-Term Prognosis

The prognosis following successful surgical resection is excellent. Most patients experience immediate resolution of constitutional symptoms (within days of surgery) and significant improvement in cardiac function.

• Follow-up: Annual echocardiographic surveillance is recommended for at least 5 years to monitor for recurrence.
• Screening: If a genetic syndrome (Carney Complex) is suspected, family screening for PRKAR1A mutations is mandatory.

8. Frequently Asked Questions (FAQ)

1. Is a cardiac myxoma cancerous?
No, it is histologically benign. However, it is clinically "malignant" because of its potential to obstruct blood flow and cause life-threatening emboli.

2. Why do I have a fever with a heart tumor?
The tumor produces inflammatory proteins, specifically Interleukin-6 (IL-6), which mimics a chronic infection or autoimmune disease.

3. Does the tumor grow back?
Recurrence is rare (1–5%) in sporadic cases but more common in familial cases. This is why lifelong follow-up is often advised.

4. Can a cardiac myxoma be treated with medication?
No. There is no pharmacological therapy that can dissolve or shrink a myxoma. Surgical resection is the only definitive treatment.

5. What happens if I don't remove it?
The tumor can grow and block the mitral valve (causing heart failure) or break off, causing a stroke or other organ infarction.

6. Is the surgery risky?
Modern cardiac surgery for myxoma is routine and highly successful, with low mortality rates. The primary intraoperative goal is complete excision without fragmentation.

7. Are there different types of myxomas?
They are generally categorized by their attachment (septal vs. non-septal) and their association with genetic syndromes (sporadic vs. Carney Complex).

8. How do doctors find the tumor?
Usually, an echocardiogram (ultrasound of the heart) is the first test that reveals the mass.

9. Can a myxoma cause a stroke?
Yes. Fragments of the tumor can break off and travel to the brain, leading to a stroke or TIA. This is a primary indication for immediate surgery.

10. What is the difference between a myxoma and a thrombus?
A thrombus is a blood clot, while a myxoma is a tumor. They can look similar on imaging, but surgeons can distinguish them during the procedure, and pathologists confirm the diagnosis via biopsy.

9. Conclusion

Cardiac myxoma remains a unique entity in cardiovascular medicine. Its ability to mimic various systemic conditions often leads to diagnostic delays. However, once identified, the path to resolution is clear. Through precise imaging, careful surgical planning, and long-term surveillance, patients with cardiac myxoma can achieve a full recovery and a normal life expectancy. Clinicians must maintain a high index of suspicion in any patient presenting with unexplained constitutional symptoms combined with new-onset cardiac murmurs.